Oncosil Medical Ltd has released a press release.
Positive Early Study Results Presented at EANM Congress
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from OncoSil Medical
- R&D Refund
- Progress update on Global Pancreatic Cancer Clinical Study
- Appendix 4E - Preliminary Final Report 30 June 2017
- First UK subject recruited
- CE Mark & Quarterly Activity Update
Later from OncoSil Medical
- Appendix 3C - Employee Loan Share Buy Back
- Additional Receipt of $0.6m R&D Tax Incentive Refund
- First Subject Recruited in the United States
- Appendix 4D & Half Yearly Report and Accounts
- Positive Early Study Results Continue
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical